Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?

The development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through wh...

Full description

Bibliographic Details
Main Authors: Suzanne E. Edwards, Chantal M. Morel, Reinhard Busse, Stephan Harbarth
Format: Article
Language:English
Published: MDPI AG 2018-12-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/7/4/111
_version_ 1818271082049699840
author Suzanne E. Edwards
Chantal M. Morel
Reinhard Busse
Stephan Harbarth
author_facet Suzanne E. Edwards
Chantal M. Morel
Reinhard Busse
Stephan Harbarth
author_sort Suzanne E. Edwards
collection DOAJ
description The development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through which industry has an important influence on antibiotic consumption and where agreements can be made alongside financial incentives, even those intended to stimulate very early research. As long as the traditional unit sale-based business model for antibiotics remains in place, profit-making incentives will likely undermine efforts to sell and utilize antibiotics in a sustainable manner. In the short-term, while we try to come to a consensus on how best to fix the market, we need measures to prevent major over-selling and inappropriate promotion—especially for new, badly needed antibiotics that reach the market. This paper explores ways in which the pharmaceutical industry could help buttress sustainable antibiotic use while we search for more long-term, constructive, mutually-beneficial ways to organize the market.
first_indexed 2024-12-12T21:20:31Z
format Article
id doaj.art-5850189e2d0145a78f68c21139e9dc98
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-12-12T21:20:31Z
publishDate 2018-12-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-5850189e2d0145a78f68c21139e9dc982022-12-22T00:11:35ZengMDPI AGAntibiotics2079-63822018-12-017411110.3390/antibiotics7040111antibiotics7040111Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?Suzanne E. Edwards0Chantal M. Morel1Reinhard Busse2Stephan Harbarth3Department of Health Care Management, Berlin University of Technology, Straße des 17. Juni 135, 10623 Berlin, GermanyInfection Control Programme, WHO Collaborating Centre, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, SwitzerlandDepartment of Health Care Management, Berlin University of Technology, Straße des 17. Juni 135, 10623 Berlin, GermanyInfection Control Programme, WHO Collaborating Centre, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, SwitzerlandThe development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through which industry has an important influence on antibiotic consumption and where agreements can be made alongside financial incentives, even those intended to stimulate very early research. As long as the traditional unit sale-based business model for antibiotics remains in place, profit-making incentives will likely undermine efforts to sell and utilize antibiotics in a sustainable manner. In the short-term, while we try to come to a consensus on how best to fix the market, we need measures to prevent major over-selling and inappropriate promotion—especially for new, badly needed antibiotics that reach the market. This paper explores ways in which the pharmaceutical industry could help buttress sustainable antibiotic use while we search for more long-term, constructive, mutually-beneficial ways to organize the market.https://www.mdpi.com/2079-6382/7/4/111antibioticsantimicrobial resistanceantibiotic consumptionmarketingpromotionpharmaceutical industryresearch and development incentiveshealth economicssustainable use
spellingShingle Suzanne E. Edwards
Chantal M. Morel
Reinhard Busse
Stephan Harbarth
Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
Antibiotics
antibiotics
antimicrobial resistance
antibiotic consumption
marketing
promotion
pharmaceutical industry
research and development incentives
health economics
sustainable use
title Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
title_full Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
title_fullStr Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
title_full_unstemmed Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
title_short Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
title_sort combatting antibiotic resistance together how can we enlist the help of industry
topic antibiotics
antimicrobial resistance
antibiotic consumption
marketing
promotion
pharmaceutical industry
research and development incentives
health economics
sustainable use
url https://www.mdpi.com/2079-6382/7/4/111
work_keys_str_mv AT suzanneeedwards combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry
AT chantalmmorel combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry
AT reinhardbusse combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry
AT stephanharbarth combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry